Stocks · News reference

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5

Aug 28, 2026, 10:50 AMBenzinga Newsdesk

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 28, 2026, 1:03 PM
RenovoRx Management to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
RenovoRx, Inc. announced that its CEO and CFO will present at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
RNXT
Fiscal.aiOct 22, 2026, 1:03 PM
RenovoRx Announces Date for Third Quarter 2026 Financial Results
RenovoRx, Inc. has scheduled the release of its third quarter 2026 financial results and business highlights for after market close on November 5, 2026.
RNXT
BenzingaOct 7, 2026, 12:35 PMBenzinga Newsdesk
RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
RNXT
BenzingaOct 1, 2026, 12:39 PMBenzinga Newsdesk
RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center
RNXT